Waterford Advisors LLC Acquires New Position in Johnson & Johnson (NYSE:JNJ)

Waterford Advisors LLC purchased a new stake in Johnson & Johnson (NYSE:JNJFree Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 1,437 shares of the company’s stock, valued at approximately $224,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of JNJ. Independent Advisor Alliance increased its stake in Johnson & Johnson by 0.9% in the 2nd quarter. Independent Advisor Alliance now owns 153,337 shares of the company’s stock valued at $25,380,000 after buying an additional 1,327 shares during the period. King Luther Capital Management Corp increased its stake in Johnson & Johnson by 0.3% in the 2nd quarter. King Luther Capital Management Corp now owns 643,435 shares of the company’s stock valued at $106,501,000 after buying an additional 2,027 shares during the period. DORCHESTER WEALTH MANAGEMENT Co grew its stake in shares of Johnson & Johnson by 0.6% during the 3rd quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 75,495 shares of the company’s stock worth $11,758,000 after purchasing an additional 414 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Johnson & Johnson by 5.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 8,843,038 shares of the company’s stock worth $1,463,594,000 after purchasing an additional 430,445 shares during the period. Finally, Cibc World Market Inc. grew its stake in shares of Johnson & Johnson by 4.4% during the 2nd quarter. Cibc World Market Inc. now owns 702,435 shares of the company’s stock worth $116,267,000 after purchasing an additional 29,891 shares during the period. Hedge funds and other institutional investors own 68.40% of the company’s stock.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $156.74 on Friday. The firm has a market cap of $377.32 billion, a price-to-earnings ratio of 11.35, a price-to-earnings-growth ratio of 2.65 and a beta of 0.53. The company has a current ratio of 1.21, a quick ratio of 0.96 and a debt-to-equity ratio of 0.37. The company’s 50-day moving average is $158.20 and its two-hundred day moving average is $158.93. Johnson & Johnson has a 12-month low of $144.95 and a 12-month high of $175.97.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. The company had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. Johnson & Johnson had a net margin of 37.79% and a return on equity of 36.75%. The firm’s quarterly revenue was down 9.7% on a year-over-year basis. During the same period in the prior year, the firm earned $2.35 EPS. Research analysts expect that Johnson & Johnson will post 10.66 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th will be given a $1.19 dividend. The ex-dividend date of this dividend is Friday, February 16th. This represents a $4.76 annualized dividend and a dividend yield of 3.04%. Johnson & Johnson’s dividend payout ratio is presently 34.47%.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on JNJ. TheStreet cut shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday, November 17th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday, January 24th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Tuesday. Finally, UBS Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and increased their price objective for the company from $167.00 to $180.00 in a research note on Friday, December 1st. Eight research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $176.14.

Get Our Latest Report on Johnson & Johnson

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.